Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2022-11-10 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in voting rights percentages held by a shareholder (Société Générale S.A.) in MorphoSys AG, referencing specific sections of the German Securities Trading Act (WpHG). This directly corresponds to the definition of reporting personal share transactions by executives or major shareholding notifications. Since the document details the acquisition/disposal of shares and crossing of voting rights thresholds (Section 5 and 6), it fits best under 'Major Shareholding Notification' (MRQ) or potentially 'Director's Dealing' (DIRS) if the shareholder was a director, but given the structure and explicit mention of 'Notification of Major Holdings' and voting rights thresholds, MRQ is the most precise fit among the provided options. It is not an AGM material, 10-K, ER, or a general regulatory filing (RNS) because it is highly specific.
2022-11-10 English
MorphoSys to Share New Data on Pelabresib and Monjuvi (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Regulatory Filings Classification · 1% confidence The document is a press release dated November 3, 2022, announcing that MorphoSys AG will present new data on its drug candidates (Pelabresib and Monjuvi) at the American Society of Hematology (ASH) Annual Meeting in December 2022. It details the specific abstracts (oral and poster presentations) that will be featured. This type of announcement, which publicizes upcoming scientific presentations and data releases, is characteristic of an Investor Presentation (IP) or a general corporate/investor relations update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it is specifically detailing scientific data to be presented to investors/the medical community, 'Investor Presentation' (IP) is the most fitting category, as it often encompasses announcements about scientific conference participation and data readouts.
2022-11-03 English
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
Regulatory Filings Classification · 1% confidence The document is a news release dated October 27, 2022, announcing preliminary results from a clinical study (Phase 1/2) for a drug candidate (Tulmimetostat). It details efficacy data, safety profiles, and mentions presentation at a scientific symposium (EORTC-NCI-AACR). The text explicitly states it is a "Media Release" and uses the EQS News service for dissemination. This content—announcing clinical trial updates and scientific findings—is characteristic of an announcement intended for investors and the public, but it is not a formal regulatory report like a 10-K, an Interim Report (IR), or a formal Earnings Release (ER). Since it is a specific announcement of scientific/clinical progress, it fits best under the general category of Investor Relations news, which often falls under Regulatory Filings (RNS) if no other specific category applies. However, given the context of presenting scientific data, it is a form of corporate communication that is not a formal financial report or a management discussion. It is a general corporate announcement disseminated via a news service. Since it is not a formal financial report, nor a management discussion, nor a specific event announcement (like dividend or capital change), the most appropriate general category for a significant, non-financial-statement corporate update disseminated via news wire is RNS (Regulatory Filings/General Announcement). It is not an Earnings Release (ER) as it focuses on clinical data, not quarterly financial performance highlights.
2022-10-27 English
GSK, MorphoSys Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
Regulatory Filings Classification · 1% confidence The document is a press release dated October 27, 2022, issued via EQS News, detailing an update on a clinical trial program (ContRAst Phase III) for a drug (Otilimab) by MorphoSys AG and its partner GSK. It announces that GSK has decided not to proceed with regulatory submissions due to limited efficacy, and plans to submit full results for publication later. This is not a full financial report (10-K or IR), an earnings release (ER), or a formal regulatory filing like a DVA or DIRS. It is an announcement concerning business/clinical development that impacts the company's outlook and pipeline. Since it is a news release about a significant business/clinical event, and it doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news releases that don't fit elsewhere, especially when distributed via a news service like EQS.
2022-10-27 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, voting rights attached to shares, and instruments (options, swaps) according to German Securities Trading Act (WpHG) sections (Article 40, Sec. 33, 34, 38). This structure perfectly matches the definition of a notification regarding changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a formal disclosure of holdings by an entity (The Goldman Sachs Group, Inc.), making MRQ the most precise fit over DVA (which is for results of shareholder votes) or DIRS (which is for director's personal trades).
2022-10-21 English
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Earnings Release Classification · 1% confidence The document is a news release dated October 21, 2022, titled "MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022." It provides preliminary sales figures for a specific product (Monjuvi) for Q3 2022 and updates the full-year financial guidance. This content structure—announcing key preliminary results and updating guidance outside of a formal quarterly report filing (like an IR or 10-K)—is characteristic of an Earnings Release (ER). It explicitly states that the full financial results will be published later (November 16, 2022), confirming this is the initial, high-level announcement. Q3 2022
2022-10-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.